Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
JCO Precision Oncology
|
April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
JCO Precision Oncology
|
April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications
|
December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology
|
July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Gynecologic Oncology
|
May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
Elizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
Page
of 2